Bladder Cancer Epidemiology Analysis and Forecast to 2033

• 1. About GlobalData
• 2. List of Contents

  • 2.1. List of Tables
  • 2.2. List of Figures

• 3. Bladder Cancer: Executive Summary

  • 3.1. Catalyst
  • 3.2. Related reports
  • 3.3. Upcoming reports

• 4. Epidemiology

  • 4.1. Disease background
  • 4.2. Risk factors and comorbidities.
  • 4.3. Global and historical trends
  • 4.4. 8MM forecast methodology.

    • 4.4.1. Sources
    • 4.4.2. Forecast assumptions and methods.
    • 4.4.3. Forecast assumptions and methods: diagnosed incident cases of bladder cancer – 8MM
    • 4.4.4. Forecast assumptions and methods: diagnosed incident cases by stage at diagnosis using the AJCC TNM staging.
    • 4.4.5. Forecast assumptions and methods: diagnosed incident cases by tumor “T” stage at diagnosis.
    • 4.4.6. Forecast assumptions and methods: diagnosed incident cases of stage Ta bladder cancer by grade
    • 4.4.7. Forecast assumptions and methods: diagnosed incident cases and diagnosed prevalent cases of bladder cancer by broad classification
    • 4.4.8. Forecast assumptions and methods: diagnosed incident cases of NMIBC by risk group
    • 4.4.9. Forecast assumptions and methods: diagnosed incident cases of bladder cancer by mutations and biomarkers.
    • 4.4.10. Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer.
    • 4.4.11. Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer by tumor stage.
    • 4.4.12. Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence.
    • 4.4.13. Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer by treatment.

• 5. Epidemiological forecast for bladder cancer (2023–33)

  • 5.1. Diagnosed incident cases of bladder cancer.
  • 5.2. Age-specific diagnosed incident cases of bladder cancer
  • 5.3. Sex-specific diagnosed incident cases of bladder cancer
  • 5.4. Diagnosed incident cases of bladder cancer by stage at diagnosis using the AJCC TNM staging.
  • 5.5. Diagnosed incident cases of bladder cancer by tumor “T” stage at diagnosis.
  • 5.6. Diagnosed incident cases of stage Ta bladder cancer by grade.
  • 5.7. Diagnosed incident cases of bladder cancer by broad classification.
  • 5.8. Diagnosed incident cases of NMIBC by risk group.
  • 5.9. Diagnosed incident cases of bladder cancer by mutations and biomarkers.
  • 5.10. Five-year diagnosed prevalent cases of bladder cancer
  • 5.11. Five-year diagnosed prevalent cases of bladder cancer by tumor stage
  • 5.12. Five-year diagnosed prevalent cases of bladder cancer by broad classification
  • 5.13. Five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence
  • 5.14. Five-year diagnosed prevalent cases of bladder cancer by treatment

• 6. Discussion

  • 6.1. Epidemiological forecast insight
  • 6.2. COVID-19 impact.
  • 6.3. Limitations of the analysis
  • 6.4. Strengths of the analysis

• 7. Appendix

  • 7.1. Bibliography
  • 7.2. About the Authors

    • 7.2.1. Epidemiologist
    • 7.2.2. Reviewers
    • 7.2.3. Vice President of Disease Intelligence and Epidemiology
    • 7.2.4. Global Head of Pharma Research, Analysis, and Competitive Intelligence

• 8. Contact Us

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbidities for bladder cancer

Table 4: 8MM, diagnosed incident cases of bladder cancer by stage at diagnosis using the AJCC TNM staging, N, both sexes, ages ≥18 years, 2023

Table 5: 8MM, diagnosed incident cases of bladder cancer by tumor “T” stage at diagnosis, N, both sexes, ages ≥18 years, 2023

Table 6: 8MM, diagnosed incident cases of bladder cancer by mutations and biomarkers, N, both sexes, ages ≥18 years, 2023

Table 7: 8MM, five-year diagnosed prevalent cases of bladder cancer by tumor stage, N, both sexes, ages ≥18 years, 2023

Figure 1: 8MM, diagnosed incident cases of bladder cancer, both sexes, N, ages ≥18 years, 2023 and 2033

Figure 2: 8MM, five-year diagnosed prevalent cases of bladder cancer, both sexes, N, ages ≥18 years, 2023 and 2033

Figure 3: 8MM, diagnosed incidence of bladder cancer, cases per 100,000 population, men, ages ≥18 years, 2013–33

Figure 4: 8MM, diagnosed incidence of bladder cancer, cases per 100,000 population, women, ages ≥18 years, 2013–33

Figure 5: 8MM, sources used and not used to forecast the diagnosed incidence of bladder cancer

Figure 6: 8MM, sources used to forecast the diagnosed incident cases by stage at diagnosis using the AJCC TNM staging

Figure 7: 8MM, sources used to forecast the diagnosed incident cases by tumor “T” stage at diagnosis

Figure 8: 8MM, sources used to forecast the diagnosed incident cases of stage Ta bladder cancer by grade

Figure 9: 8MM, sources used to forecast the diagnosed incident cases of bladder cancer and five-year diagnosed prevalent cases of bladder cancer by broad classification

Figure 10: 8MM, sources used to forecast the diagnosed incident cases of NMIBC by risk group

Figure 11: 8MM, sources used to forecast the diagnosed incident cases of bladder cancer by mutations and biomarkers

Figure 12: 8MM, sources used to forecast the five-year diagnosed prevalent cases of bladder cancer

Figure 13: 8MM, sources used to forecast the five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence

Figure 14: 8MM, sources used to forecast the five-year diagnosed prevalent cases of bladder cancer by treatment

Figure 15: 8MM, diagnosed incident cases of bladder cancer, N, both sexes, ages ≥18 years, 2023

Figure 16: 8MM, diagnosed incident cases of bladder cancer by age, N, both sexes, 2023

Figure 17: 8MM, diagnosed incident cases of bladder cancer by sex, N, ages ≥18 years, 2023

Figure 18: 8MM, diagnosed incident cases of stage Ta bladder cancer by grade, N, both sexes, ages ≥18 years, 2023

Figure 19: 8MM, diagnosed incident cases of bladder cancer by broad classification, N, both sexes, ages ≥18 years, 2023

Figure 20: 8MM, diagnosed incident cases of NMIBC by risk group, N, both sexes, ages ≥18 years, 2023

Figure 21: 8MM, five-year diagnosed prevalent cases of bladder cancer, N, both sexes, ages ≥18 years, 2023

Figure 22: 8MM, five-year diagnosed prevalent cases of bladder cancer by broad classification, N, both sexes, ages ≥18 years, 2023

Figure 23: 8MM, five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence, N, both sexes, ages ≥18 years, 2023

Figure 24: 8MM, five-year diagnosed prevalent cases of bladder cancer by treatment, N, both sexes, ages ≥18 years, 2023